BG102716A - Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline - Google Patents

Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline

Info

Publication number: BG102716A
Authority: BG; Bulgaria
Prior art keywords: treatment; endotheline; formulations; opposing; cardiac insufficiency
Prior art date: 1996-04-04

Application number

BG102716A

Other languages

Bulgarian (bg)

English (en)

Inventor

Joseph Lynch

You-Tang Shen

Original Assignee

Joseph Lynch

You-Tang Shen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-04

Filing date

1998-08-21

Publication date

1999-09-30

1998-08-21 Application filed by Joseph Lynch, You-Tang Shen filed Critical Joseph Lynch

1999-09-30 Publication of BG102716A publication Critical patent/BG102716A/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Materials For Photolithography (AREA)
Photosensitive Polymer And Photoresist Processing (AREA)

BG102716A 1996-04-04 1998-08-21 Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline BG102716A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1488296P	1996-04-04	1996-04-04
PCT/US1997/003737 WO1997037665A1 (en)	1996-04-04	1997-03-19	Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number	Publication Date
BG102716A true BG102716A (en)	1999-09-30

Family

ID=21768326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG102716A BG102716A (en)	1996-04-04	1998-08-21	Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline

Country Status (25)

Country	Link
US (3)	US5834483A (es)
EP (1)	EP0906108B1 (es)
JP (2)	JP3345891B2 (es)
KR (1)	KR20000005178A (es)
CN (1)	CN1215335A (es)
AT (1)	ATE297739T1 (es)
AU (1)	AU723351B2 (es)
BG (1)	BG102716A (es)
BR (1)	BR9708525A (es)
CA (1)	CA2249330C (es)
CZ (1)	CZ296098A3 (es)
DE (1)	DE69733557T2 (es)
EA (1)	EA003587B1 (es)
EE (1)	EE9800315A (es)
ES (1)	ES2241047T3 (es)
HU (1)	HUP9903893A3 (es)
IL (1)	IL126175A (es)
IS (1)	IS4847A (es)
NO (1)	NO984564L (es)
NZ (1)	NZ331789A (es)
PL (1)	PL329077A1 (es)
SK (1)	SK130098A3 (es)
TR (1)	TR199801988T2 (es)
UA (1)	UA50761C2 (es)
WO (1)	WO1997037665A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2249330C (en)	1996-04-04	2005-08-09	Banyu Pharmaceutical Co., Ltd.	Method of treating heart failure with endothelin antagonists
WO1998006700A1 (en) *	1996-08-09	1998-02-19	Merck & Co., Inc.	Stereoselective deoxygenation reaction
ATE259800T1 (de)	1998-01-21	2004-03-15	Banyu Pharma Co Ltd	Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1577310A1 (en) *	2002-12-27	2005-09-21	Kaneka Corporation	Processes for producing optically active 2-thiomethyl-3-phenylpropionic acid derivative and for producing intermediate therefor
BRPI0416628A (pt)	2003-11-17	2007-01-16	Novartis Ag	uso de compostos orgánicos
GB0327839D0 (en)	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
JP2007529459A (ja)	2004-03-17	2007-10-25	ノバルティスアクチエンゲゼルシャフト	治療に置けるレニン阻害剤の使用
JP4967136B2 (ja)	2005-06-24	2012-07-04	国立大学法人東京医科歯科大学	薬剤溶出性ステント
WO2011116115A1 (en)	2010-03-16	2011-09-22	Novartis Ag	Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4971959A (en) *	1987-04-14	1990-11-20	Warner-Lambert Company	Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) *	1990-04-05	1990-06-06	Beecham Group Plc	Novel compounds
US5565485A (en) *	1993-03-19	1996-10-15	Merck & Co., Inc.	Biphenyl compounds useful or endothelin antagonists
US5571813A (en) *	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
ATE199151T1 (de) *	1993-08-18	2001-02-15	Banyu Pharma Co Ltd	Kondensierte heteroaromatische cyclopentenderivate mit endothelin- antagonistischer aktivität
US5389620A (en) *	1993-08-18	1995-02-14	Banyu Pharmaceutical Co., Ltd.	Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) *	1995-01-05	1997-08-19	Warner-Lambert Company	Phenylalanine derivatives as endothelin antagonists
CA2249330C (en) *	1996-04-04	2005-08-09	Banyu Pharmaceutical Co., Ltd.	Method of treating heart failure with endothelin antagonists

1997
- 1997-03-19 CA CA002249330A patent/CA2249330C/en not_active Expired - Fee Related
- 1997-03-19 SK SK1300-98A patent/SK130098A3/sk unknown
- 1997-03-19 NZ NZ331789A patent/NZ331789A/xx unknown
- 1997-03-19 JP JP53619497A patent/JP3345891B2/ja not_active Expired - Fee Related
- 1997-03-19 AU AU22025/97A patent/AU723351B2/en not_active Ceased
- 1997-03-19 UA UA98105222A patent/UA50761C2/uk unknown
- 1997-03-19 PL PL97329077A patent/PL329077A1/xx unknown
- 1997-03-19 HU HU9903893A patent/HUP9903893A3/hu unknown
- 1997-03-19 EP EP97914955A patent/EP0906108B1/en not_active Expired - Lifetime
- 1997-03-19 WO PCT/US1997/003737 patent/WO1997037665A1/en active IP Right Grant
- 1997-03-19 EA EA199800889A patent/EA003587B1/ru not_active IP Right Cessation
- 1997-03-19 CZ CZ982960A patent/CZ296098A3/cs unknown
- 1997-03-19 DE DE69733557T patent/DE69733557T2/de not_active Expired - Lifetime
- 1997-03-19 BR BR9708525A patent/BR9708525A/pt not_active Application Discontinuation
- 1997-03-19 KR KR1019980707850A patent/KR20000005178A/ko not_active Application Discontinuation
- 1997-03-19 AT AT97914955T patent/ATE297739T1/de not_active IP Right Cessation
- 1997-03-19 ES ES97914955T patent/ES2241047T3/es not_active Expired - Lifetime
- 1997-03-19 EE EE9800315A patent/EE9800315A/xx unknown
- 1997-03-19 TR TR1998/01988T patent/TR199801988T2/xx unknown
- 1997-03-19 CN CN97193645A patent/CN1215335A/zh active Pending
- 1997-03-19 IL IL12617597A patent/IL126175A/xx not_active IP Right Cessation
- 1997-03-26 US US08/824,848 patent/US5834483A/en not_active Expired - Fee Related
1998
- 1998-08-11 US US09/132,514 patent/US6087360A/en not_active Expired - Lifetime
- 1998-08-21 BG BG102716A patent/BG102716A/xx unknown
- 1998-09-15 IS IS4847A patent/IS4847A/is unknown
- 1998-09-30 NO NO984564A patent/NO984564L/no not_active Application Discontinuation
2000
- 2000-02-22 US US09/507,666 patent/US6380195B1/en not_active Expired - Fee Related
2001
- 2001-12-07 JP JP2001374870A patent/JP2002220337A/ja active Pending

Also Published As

Publication number	Publication date
KR20000005178A (ko)	2000-01-25
EA199800889A1 (ru)	1999-04-29
US6087360A (en)	2000-07-11
TR199801988T2 (xx)	2000-08-21
HUP9903893A2 (hu)	2001-04-28
IL126175A0 (en)	1999-05-09
BR9708525A (pt)	1999-08-03
CZ296098A3 (cs)	1999-06-16
NZ331789A (en)	2000-05-26
ES2241047T3 (es)	2005-10-16
EP0906108B1 (en)	2005-06-15
JP3345891B2 (ja)	2002-11-18
JP2002220337A (ja)	2002-08-09
AU723351B2 (en)	2000-08-24
CA2249330C (en)	2005-08-09
EE9800315A (et)	1999-06-15
IS4847A (is)	1998-09-15
UA50761C2 (uk)	2002-11-15
ATE297739T1 (de)	2005-07-15
US6380195B1 (en)	2002-04-30
JP2000510824A (ja)	2000-08-22
CN1215335A (zh)	1999-04-28
EA003587B1 (ru)	2003-06-26
PL329077A1 (en)	1999-03-15
NO984564D0 (no)	1998-09-30
NO984564L (no)	1998-12-04
DE69733557D1 (de)	2005-07-21
HUP9903893A3 (en)	2001-05-28
DE69733557T2 (de)	2005-11-03
IL126175A (en)	2003-05-29
EP0906108A4 (en)	2000-12-06
EP0906108A1 (en)	1999-04-07
US5834483A (en)	1998-11-10
CA2249330A1 (en)	1997-10-16
WO1997037665A1 (en)	1997-10-16
AU2202597A (en)	1997-10-29
SK130098A3 (en)	1999-05-07

Publication	Publication Date	Title
UA26213C2 (uk)	1999-07-19	Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
UA39158C2 (uk)	2001-06-15	Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MY117032A (en)	2004-04-30	A novel compound form.
IL121170A0 (en)	1997-11-20	Compositions for the treatment of dermatological disorders
EP0626174A3 (en)	1996-01-03	Method and composition for the prophylaxis and / or treatment of underactive organs.
PL328858A1 (en)	1999-03-01	Immunogenous peptides
IL110943A0 (en)	1994-11-28	Compositions for the treatment of skin disorders
EP0961613A4 (en)	2003-07-23	METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE RESORPTION DISORDERS, INCLUDING OSTEOPOROSIS
ZA943744B (en)	1995-04-26	Therapeutic substituted guanidines
AU2160492A (en)	1993-01-12	Treatment of human diseases involving dysregulation or dysfunction of the nervous system
HUP9903166A3 (en)	2003-09-29	Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
GB8900678D0 (en)	1989-03-08	Compositions for the prevention and medical treatment of parodonthopathy
BG102818A (en)	1999-05-31	D-manitol and method for its preparation
GB2311940B (en)	2000-07-19	Pharmaceutical compositions for the treatment of rhinitis
BG102716A (en)	1999-09-30	Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
MX9703944A (es)	1998-05-31	Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
MXPA94009086A (es)	2006-02-14	Guanidinas sustituidas terapeuticas.
IN167848B (es)	1990-12-29
BG102667A (en)	1999-02-26	Diosgenine-containing composition
IL111805A0 (en)	1995-01-24	Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
GR76280B (es)	1984-08-04
GB9510162D0 (en)	1995-07-12	Compositions for the treatment of skin conditions
ZA949564B (en)	1995-08-16	Method for treating constipation using dimeticone.
DE59104412D1 (de)	1995-03-09	Dynamische Redressionsschiene zur Therapie der Vorfussadduktion.
HUP9901183A3 (en)	1999-11-29	Compositions and methods for the prevention and treatment of oral mucositis